Health Catalyst earnings release, May 11, 2026

Health Catalyst, Inc. (HCAT) · Form 8-K, Item 2.02 · Filed · SEC filing

Health Catalyst Reports First Quarter 2026 Results

SALT LAKE CITY, UT, May 11, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended March 31, 2026.

“We delivered solid first quarter results, with revenue and adjusted EBITDA exceeding expectations,” said Ben Albert, Chief Executive Officer of Health Catalyst. “More importantly, this quarter we took the first decisive step toward transforming our operating model and aligning the company around its highest-conviction technology opportunities. This is not a short-term cost exercise. It is a strategic reset designed to build a more focused, durable Health Catalyst capable of meeting the opportunity in front of us. I am confident in the leadership team and board we have assembled to build the intelligence-driven technology company healthcare needs.”

Financial Highlights for the Three Months Ended March 31, 2026

Key Financial Measures

________________________

Financial statements

Income Statement

Three Months Ended March 31, — Key Financial Measures (in thousands, except percentages, unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025Year over Year Change
Total revenue70,75679,413-11.0%
Gross profit27,72628,659-3.0%
Gross margin39.0%36.0%
Net loss-111,026-23,742-368.0%
Non-GAAP Financial Measures:(1)Adjusted Gross Profit36,43939,048-7.0%
Non-GAAP Financial Measures:(1)Adjusted Gross Margin51.0%49.0%
Non-GAAP Financial Measures:(1)Adjusted EBITDA9,1376,27946.0%

Income Statement

Three Months Ended March 31, — (in thousands, except per share data, unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenue:Technology49,46851,482
Revenue:Professional services21,28827,931
Revenue:Total revenue70,75679,413
Cost of revenue, excluding depreciation and amortization:Technology(1)(2)(3)17,28317,565
Cost of revenue, excluding depreciation and amortization:Professional services(1)(2)(3)18,01025,613
Cost of revenue, excluding depreciation and amortization:Total cost of revenue, excluding depreciation and amortization35,29343,178
Operating expenses:Sales and marketing(1)(2)(3)10,58514,738
Operating expenses:Research and development(1)(2)(3)9,77915,186
Operating expenses:General and administrative(1)(2)(3)13,96014,162
Operating expenses:Depreciation and amortization12,11512,320
Operating expenses:Impairment of goodwill95,501
Operating expenses:Total operating expenses141,94056,406
Operating expenses:Loss from operations-106,477-20,171
Operating expenses:Interest and other expense, net-4,135-3,356
Operating expenses:Loss before income taxes-110,612-23,527
Operating expenses:Income tax provision-414-215
Operating expenses:Net loss-111,026-23,742
Operating expenses:Net loss per share, basic and diluted-1.53-0.35
Operating expenses:Weighted-average shares outstanding used in calculating net loss per share, basic and diluted72,59368,552

Income Statement

Three Months Ended March 31, — Includes stock-based compensation expense as follows: (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Technology118219
Professional services5491,002
Sales and marketing7962,162
Research and development5901,133
General and administrative1,7173,027
Total3,7707,543

Income Statement

Three Months Ended March 31, — (2) Includes acquisition-related costs, net, as follows: (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Technology174
Professional services6120
Sales and marketing3498
Research and development6167
General and administrative2,4212,170
Total2,4373,029

Income Statement

Three Months Ended March 31, — (3) Includes restructuring costs as follows: (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Technology401
Professional services302997
Sales and marketing109352
Research and development1001,672
General and administrative1,280136
Total1,7913,558

Income Statement

Three Months Ended March 31, 2026 (in thousands, except percentages)

Three Months Ended March 31, 2026 – TechnologyThree Months Ended March 31, 2026 – Professional ServicesThree Months Ended March 31, 2026 – Total
Revenue49,46821,28870,756
Cost of revenue, excluding depreciation and amortization-17,283-18,010-35,293
Amortization of intangible assets, cost of revenue-4,190-4,190
Depreciation of property and equipment, cost of revenue-3,547-3,547
Gross profit24,4483,27827,726
Gross margin491539
Add:Amortization of intangible assets, cost of revenue4,1904,190
Add:Depreciation of property and equipment, cost of revenue3,5473,547
Add:Stock-based compensation118549667
Add:Acquisition-related costs, net(1)167
Add:Restructuring costs(2)302302
Add:Adjusted Gross Profit32,3044,13536,439
Add:Adjusted Gross Margin651951

Income Statement

Three Months Ended March 31, 2025 (in thousands, except percentages)

Three Months Ended March 31, 2025 – TechnologyThree Months Ended March 31, 2025 – Professional ServicesThree Months Ended March 31, 2025 – Total
Revenue51,48227,93179,413
Cost of revenue, excluding depreciation and amortization-17,565-25,613-43,178
Amortization of intangible assets, cost of revenue-4,596-4,596
Depreciation of property and equipment, cost of revenue-2,980-2,980
Gross profit26,3412,31828,659
Gross margin51836
Add:Amortization of intangible assets, cost of revenue4,5964,596
Add:Depreciation of property and equipment, cost of revenue2,9802,980
Add:Stock-based compensation2191,0021,221
Add:Acquisition-related costs, net(1)74120194
Add:Restructuring costs(2)4019971,398
Add:Adjusted Gross Profit34,6114,43739,048
Add:Adjusted Gross Margin671649

Income Statement

Three Months Ended March 31, (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net loss-111,026-23,742
Add:Interest and other expense, net4,1353,356
Add:Income tax provision414215
Add:Depreciation and amortization12,11512,320
Add:Stock-based compensation3,7707,543
Add:Acquisition-related costs, net(1)2,4373,029
Add:Restructuring costs(2)1,7913,558
Add:Impairment of goodwill(3)95,501
Add:Adjusted EBITDA9,1376,279

Income Statement

Three Months Ended March 31, (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Total operating expenses141,94056,406
Less:Depreciation and amortization-12,115-12,320
Less:Stock-based compensation-3,103-6,322
Less:Acquisition-related costs, net(1)-2,430-2,835
Less:Impairment of goodwill(2)-95,501
Less:Restructuring costs(3)-1,489-2,160
Less:Adjusted Operating Expenses27,30232,769
Less:Total operating expenses as a % of revenue20171
Less:Adjusted Operating Expenses as a % of revenue3941

Income Statement

Three Months Ended March 31, (in thousands, except share and per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net loss-111,026-23,742
Add:Stock-based compensation3,7707,543
Add:Amortization of acquired intangibles8,1138,732
Add:Restructuring costs(1)1,7913,558
Add:Acquisition-related costs, net(2)2,4373,029
Add:Impairment of goodwill(3)95,501
Add:Non-cash interest expense related to debt facilities6331,208
Add:Adjusted Net Income1,219328
Denominator:Weighted-average shares outstanding used in calculating net loss per share, basic and diluted, and Adjusted Net Income per share, basic72,593,21068,552,084
Denominator:Non-GAAP dilutive effect of stock-based awards622,525225,507
Denominator:Non-GAAP weighted-average shares outstanding used in calculating Adjusted Net Income per share, diluted73,215,73568,777,591
Denominator:Net loss per share, basic and diluted-1.53-0.35
Denominator:Adjusted Net Income per share, basic and diluted0.020.01

Balance Sheet

As of March 31, — (in thousands, except share and per share data, unaudited)

As of March 31, – 2026 – (unaudited)As of December 31, – 2025
Current assets:Cash and cash equivalents59,86450,814
Current assets:Short-term investments48,95944,918
Current assets:Accounts receivable, net59,14659,128
Current assets:Prepaid expenses and other assets14,34314,447
Current assets:Total current assets182,312169,307
Current assets:Property and equipment, net34,93533,838
Current assets:Intangible assets, net69,33277,678
Current assets:Operating lease right-of-use assets6,2556,640
Current assets:Goodwill113,251209,073
Current assets:Other assets6,1176,107
Current assets:Total assets412,202502,643
Current liabilities:Accounts payable11,6949,363
Current liabilities:Accrued liabilities20,82518,697
Current liabilities:Deferred revenue69,73656,107
Current liabilities:Operating lease liabilities3,7313,779
Current liabilities:Current portion of long-term debt1,6271,627
Current liabilities:Total current liabilities107,61389,573
Current liabilities:Long-term debt, net of current portion151,738151,624
Current liabilities:Deferred revenue, net of current portion227410
Current liabilities:Operating lease liabilities, net of current portion13,48214,208
Current liabilities:Contingent consideration liabilities, net of current portion156250
Current liabilities:Other liabilities841798
Current liabilities:Total liabilities274,057256,863
Stockholders’ equity:Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 73,748,666 and 72,027,332 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1,612,8081,608,840
Stockholders’ equity:Accumulated deficit-1,475,672-1,364,646
Stockholders’ equity:Accumulated other comprehensive income1,0091,586
Stockholders’ equity:Total stockholders’ equity138,145245,780
Stockholders’ equity:Total liabilities and stockholders’ equity412,202502,643

Cash Flow

Three Months Ended March 31, — (in thousands, unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Cash flows from operating activitiesNet loss-111,026-23,742
Adjustments to reconcile net loss to net cash provided by operating activities:Stock-based compensation expense3,7707,543
Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization12,11512,320
Adjustments to reconcile net loss to net cash provided by operating activities:Non-cash operating lease expense625735
Adjustments to reconcile net loss to net cash provided by operating activities:Amortization of debt discount, issuance costs, and deferred financing costs6331,208
Adjustments to reconcile net loss to net cash provided by operating activities:Investment discount and premium accretion-227-914
Adjustments to reconcile net loss to net cash provided by operating activities:Provision for expected credit losses555810
Adjustments to reconcile net loss to net cash provided by operating activities:Deferred tax provision4467
Full release

(1) These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying "Non-GAAP Financial Measures" section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.

Financial Outlook

Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.

For the second quarter of 2026, we expect:

• Total revenue of $68 million to $70 million, and

• Adjusted EBITDA of $9 million to $10 million.

For the full year of 2026, we expect:

• Total revenue of $260 million to $265 million, and

• Adjusted EBITDA of $30 million to $33 million.

We have not provided forward-looking guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and therefore have not reconciled guidance for Adjusted EBITDA to net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably forecasted.

Quarterly Conference Call Details

We will host a conference call to review the results today, Wednesday, May 11, 2026, at 5:00 p.m. E.T. The conference call can be accessed by dialing (800) 343-5172 for U.S. participants, or (203) 518-9856 for international participants, and referencing conference ID “HCATQ126.” A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Health Catalyst

Health Catalyst, Inc. (Nasdaq: HCAT) is a healthcare intelligence company that accelerates measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes, Health Catalyst helps health systems move from data to confident, measurable action.

Available Information

Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our company through a variety of means, including our website (https://www.healthcatalyst.com/), our investor relations website (https://ir.healthcatalyst.com/), press releases, SEC filings, public conference calls, and social media, including our (https://www.linkedin.com/company/healthcatalyst) and our CEO’s social media accounts such as LinkedIn (https://www.linkedin.com/in/ben-albert-0a763b1/), in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth, our growth strategies, our strategic priorities, our DOS to Ignite migration expectations, and our financial outlook for the second quarter and full year 2026. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.... (truncated)etailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, expected to be filed with the SEC on or about May 11, 2026, and the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data, unaudited)

Condensed Consolidated Statements of Operations

(in thousands, except per share data, unaudited)

_______________

(1)

Includes stock-based compensation expense as follows:

(2) Includes acquisition-related costs, net, as follows:

(3) Includes restructuring costs as follows:

Condensed Consolidated Statements of Cash Flows

(in thousands, unaudited)

Non-GAAP Financial Measures

To supplement our financial information presented in accordance with GAAP, we believe certain non-GAAP financial measures, including Adjusted Gross Profit, Adjusted Gross Margin, Adjusted EBITDA, Adjusted Cost of Revenue, Adjusted Operating Expenses, Adjusted Net Income, and Adjusted Net Income per share, basic and diluted, are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because it is non-cash in nature and excluding this expense provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies. We use this non-GAAP financial information to evaluate our ongoing operations, as a component in determining employee bonus compensation, and for internal planning and forecasting purposes.

We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Gross Profit and Adjusted Gross Margin

Gross profit is a GAAP financial measure that is calculated as revenue less cost of revenue, including depreciation and amortization of capitalized software development costs and acquired technology. We calculate gross margin as gross profit divided by our revenue. Adjusted Gross Profit is a non-GAAP financial measure that we define as gross profit, adjusted for (i) depreciation and amortization, (ii) stock-based compensation, (iii) acquisition-related costs, net, and (iv) restructuring costs, as applicable. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors as they eliminate the impact of certain non-cash expenses and allow a direct comparison of these measures between periods without the impact of non-cash expenses and certain other non-recurring operating expenses.

We present both of these measures for our technology and professional services business. We believe these non-GAAP financial measures are useful in evaluating our operating performance compared to that of other companies in our industry, as these metrics generally eliminate the effects of certain items that may vary from company to company for reasons unrelated to overall profitability.

The following is a reconciliation of our Adjusted Gross Profit and Adjusted Gross Margin, in total and for technology and professional services, to gross profit and gross margin, the most directly comparable financial measures calculated in accordance with GAAP for the three months ended March 31, 2026 and 2025.

___________________

(1)

Acquisition-related costs, net include deferred retention expenses attributable to the KPI Ninja acquisition. For additional details refer to Notes 1 and 2 in our condensed consolidated financial statements.

(2)

Restructuring costs include severance and other team member costs from workforce reductions. For additional details, refer to Note 19 in our condensed consolidated financial statements.

___________________

(1)

Acquisition-related costs, net include deferred retention expenses attributable to the Upfront, Intraprise, ARMUS and KPI Ninja acquisitions. For additional details refer to Notes 1 and 2 in our condensed consolidated financial statements.

(2)

Restructuring costs include severance and other team member costs from workforce reductions. For additional details, refer to Note 19 in our condensed consolidated financial statements.

Adjusted EBITDA... (truncated)bilities for potential earn-out payments, (vi) restructuring costs, (vii) impairment of goodwill, and (viii) non-recurring lease-related charges, as applicable. We view acquisition-related expenses when applicable, such as transaction costs (including third-party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations) and changes in the fair value of contingent consideration liabilities that are directly related to business combinations, as costs that are unpredictable, dependent upon factors outside of our control, and are not necessarily reflective of operational performance during a period. We believe that excluding restructuring costs, impairment of goodwill and intangible assets, and non-recurring lease-related charges, as applicable, allows for more meaningful comparisons between operating results from period to period as these are separate from the core activities that arise in the ordinary course of our business and are not part of our ongoing operations. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and a comparison with our past financial performance, and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of our Adjusted EBITDA to net loss, the most directly comparable financial measure calculated in accordance with GAAP, for the three months ended March 31, 2026 and 2025:

__________________

(1)

Acquisition-related costs, net include third-party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, and changes in fair value of contingent consideration liabilities for potential earn-out payments. For additional details refer to Notes 1, 2 and 7 in our condensed consolidated financial statements.

(2)

Restructuring costs include severance and other team member costs from workforce reductions, as well as legal and advisory fees related to shareholder activism defense costs regarding our former CEO’s retirement and transition in the first quarter of 2026 and significant board of director refreshment that are non-recurring and outside the ordinary course of our business. For additional details, refer to Note 19 in our condensed consolidated financial statements.

(3)

Impairment of goodwill was recognized as a result of impairment indicators and quantitative tests indicating the fair value of the Technology reporting unit was below the carrying value as of March 31, 2026. For additional details, refer to Note 4 in our condensed consolidated financial statements.

Adjusted Cost of Revenue

Adjusted Cost of Revenue is a non-GAAP financial measure that we define as cost of revenue adjusted for (i) depreciation and amortization, (ii) stock-based compensation, (iii) acquisition-related costs, net, and (iv) restructuring costs, as applicable. We view these adjustments to allow for more meaningful comparisons between operating results from period-to-period as these are separate from the core activities that arise in the ordinary course of our business. Adjusted Cost of Revenue is also computable by subtracting Adjusted Gross Profit from revenue. We believe Adjusted Cost of Revenue provides investors with useful information on period-to-period performance as evaluated by management and a comparison with our past financial performance, and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of Adjusted Cost of Revenue to our cost of revenue, the most directly comparable financial measure calculated in accordance with GAAP, for the three months ended March 31, 2026 and 2025:

__________________

(1)

Acquisition-related costs, net include deferred retention expenses incurred as part of business combinations.

(2)

Restructuring costs include severance and other team member costs from workforce reductions. For additional details, refer to Note 19 in our condensed consolidated financial statements.

Adjusted Operating Expenses

Adjusted Operating Expenses is a non-GAAP financial measure that we define as total operating expenses adjusted for (i) depreciation and amortization, (ii) stock-based compensation, (iii) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities for potential earn-out payments, (iv) impairment of goodwill, and (v) restructuring costs, as applicable. We view these adjustments to allow for more meaningful comparisons between operating results from period-to-period as these are separate from the core activities that arise in the ordinary course of our business. We believe Adjusted Operating Expenses provides investors with useful information on period-to-period performance as evaluated by management and a comparison with our past financial performance, and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of Adjusted Operating Expenses to our total operating expenses, the most directly comparable financial measure calculated in accordance with GAAP, as well as a calculation of total operating expenses and Adjusted Operating Expenses as a percentage of total revenue, for the three months ended March 31, 2026 and 2025:

__________________

(1)... (truncated)ted costs, net include third-party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, and changes in fair value of contingent consideration liabilities for potential earn-out payments.

(2)

Impairment of goodwill was recognized as a result of impairment indicators and quantitative tests indicating the fair values of the Technology reporting unit was below the carrying values as of March 31, 2026. For additional details, refer to Note 4 in our condensed consolidated financial statements.

(3)

Restructuring costs include severance and other team member costs from workforce reductions, as well as legal and advisory fees related to shareholder activism defense costs regarding our former CEO’s retirement and transition in the first quarter of 2026 and significant board of director refreshment that are non-recurring and outside the ordinary course of our business. For additional details, refer to Note 19 in our condensed consolidated financial statements.

Adjusted Net Income and Adjusted Net Income Per Share

Adjusted Net Income is a non-GAAP financial measure that we define as net loss adjusted for (i) stock-based compensation, (ii) amortization of acquired intangibles, (iii) restructuring costs, (iv) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities, (v) impairment of goodwill, and (vi) non-cash interest expense related to debt facilities, as applicable. We believe Adjusted Net Income provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of Adjusted Net Income to our net loss, the most directly comparable financial measure calculated in accordance with GAAP, for the three months ended March 31, 2026 and 2025:

______________

(1)

Restructuring costs include severance and other team member costs from workforce reductions, as well as legal and advisory fees related to shareholder activism defense costs regarding our former CEO’s retirement and transition in the first quarter of 2026 and significant board of director refreshment that are non-recurring and outside the ordinary course of our business. For additional details, refer to Note 19 in our condensed consolidated financial statements.

(2)

Acquisition-related costs, net includes third-party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, and changes in fair value of contingent consideration liabilities for potential earn-out payments.

(3)

Impairment of goodwill and intangible assets was recognized as a result of impairment indicators and quantitative tests indicating the fair values of the Technology reporting unit was below the carrying values as of March 31, 2026. For additional details, refer to Note 4 in our condensed consolidated financial statements.

DOS to Ignite Migration Potential Churn Analysis

The graphic below outlines our current expectations regarding annual recurring revenue (ARR) potentially at risk in connection with DOS to Ignite migration, as well as details regarding clients that have provided notice regarding churn or down-sell in connection with DOS to Ignite migration that will negatively impact ARR in 2026 and 2027. As described below, our current expectation is that we retain a portion of the potentially at-risk ARR and we expect a portion of the potentially at-risk ARR may churn or down-sell in 2026 and 2027, despite our efforts to retain those relationships. We view certain portions of this ARR to be likely to churn or down-sell; however, we have strategies and initiatives in place that aim to retain this ARR.

Health Catalyst Investor Relations Contact:

Stephanie St. Clair

Finance and Investor Relations, SVP

+1 (855)-309-6800 ir@healthcatalyst.com

Health Catalyst Media Contact:

Kathryn Larson

Director, Public Relations and Communications media@healthcatalyst.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Health Catalyst earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.